The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings.

This study analyzed the characteristics of 257 HLA-identical sibling transplants of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells depleted of T cells by CD34(+) positive selection (allo-PBT/CD34(+)) for their effect on the incidence of graft failure. Twenty-four patients developed graft failure (actuarial probability, 11%; 95% confidence interval, 7.1-14. 9). Prognostic factors considered were sex and age of donor and recipient, donor-recipient blood group compatibility, diagnosis, disease status at transplant, conditioning regimen, cytomegalovirus serology, number of CD34(+) and CD3(+) cells infused, and cryopreservation. The major factor associated with graft failure was the number of CD3(+) cells in the inoculum. Twenty-three of 155 patients receiving a T-cell dose in the graft less than or equal to 0.2 x 10(6)/kg experienced graft failure, compared with only one of 102 patients receiving more than 0.2 x 10(6)/kg (actuarial probability 18% vs 1%, respectively; P =.0001). The actuarial probability of graft failure progressively increased as the number of CD3(+) cells in the graft decreased, which was determined by grouping the number of CD3(+) cells in quartiles (log-rank P =.03; log-rank for trend P =.003). In the multivariate analysis by the proportional hazard method, 2 covariates entered into regression at a significant level: CD3(+) cells less than or equal to 0.2 x 10(6)/kg (risk ratio = 17; P <.0001), and patients with chronic myelogenous leukemia (CML) conditioned with busulphan-based regimens (risk ratio = 4.8; P =.001). From these results it appears that the number of CD3(+) cells in the inoculum-with a threshold of 0.2 x 10(6)/kg or less-is the most critical factor in maintaining a sustained engraftment in allo-PBT/CD34(+) from HLA-identical siblings. In addition, for patients with CML receiving 0.2 x 10(6)/kg or less CD3(+) cells, total body irradiation might be better than busulphan-based regimens.

[1]  N. Villamor,et al.  Enumeration of CD4(+) T-cells in the peripheral blood of HIV-infected patients: an interlaboratory study of the FACSCount system. , 1999, Cytometry.

[2]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[3]  J. Garcia-conde,et al.  Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique , 1998, Bone Marrow Transplantation.

[4]  J. Briones,et al.  Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. , 1997, Blood.

[5]  Y. Reisner,et al.  Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice , 1995, Nature Medicine.

[6]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[7]  B. Glass,et al.  Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplatition in a murine model , 1994, British journal of haematology.

[8]  H. Nieuwenhuis,et al.  Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft [see comments] , 1994 .

[9]  H. Heimpel,et al.  Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. , 1993, Bone marrow transplantation.

[10]  P. Martin,et al.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.

[11]  B. Glass,et al.  Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. , 1992, Blood.

[12]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[13]  J. Voltarelli,et al.  In vitro comparison of two methods of T cell depletion associated with different rates of graft failure after allogeneic marrow transplantation. , 1990, Bone marrow transplantation.

[14]  G. Vogelsang,et al.  Graft-versus-host disease. , 1990, Hematology/oncology clinics of North America.

[15]  T. Lapidot,et al.  Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Murphy,et al.  An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. , 1990, Journal of immunology.

[17]  J. Raemaekers,et al.  Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. , 1990, Blood.

[18]  C. Bordignon,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. , 1989, Blood.

[19]  H. Deeg,et al.  Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. , 1988, Bone marrow transplantation.

[20]  S. Mackinnon,et al.  Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation. , 1988, Leukemia.

[21]  G. Hale,et al.  T CELL DEPLETION WITH CAMPATH‐1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION , 1988, Transplantation.

[22]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[23]  D. Arthur,et al.  Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. , 1987, Transplantation.

[24]  E. Archimbaud,et al.  GRAFT REJECTION AFTER T‐CELL DEFLECTED MARROW TRANSPLANTATION: ROLE OF FRACTIONATED IRRADIATION , 1987, British journal of haematology.

[25]  A. Hagenbeek,et al.  Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. , 1986, Bone marrow transplantation.

[26]  L. VázquezSell,et al.  Graft-versus-host disease. , 1991, The New England journal of medicine.

[27]  J. Gribben,et al.  Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation , 1986, British journal of haematology.

[28]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[29]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[30]  K. Sullivan,et al.  Factors associated with graft rejection after HLA‐identical marrow transplantation for aplastic anaemia , 1983, British journal of haematology.

[31]  Brenda,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. , 1989, Blood.

[32]  D. V. van Bekkum.  Retrospectives and perspectives in bone marrow transplantation. , 1989, Bone marrow transplantation.

[33]  J. Bennett,et al.  Treatment of refractory acute leukaemia with aclacinomycin A. , 1989, Bone marrow transplantation.

[34]  B. Löwenberg,et al.  Bone Marrow Transplan- tation: Biological Mechanisms and Clinical Practice , 1985 .